USD
$0.00
(0.00%
)At Close (As of Oct 14, 2025)
$3.06B
Market Cap
975
P/E Ratio
0.01
EPS
$10.68
52 Week High
$6.68
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $1B |
Total Revenue | $2.8B |
Cost Of Revenue | $1.8B |
Costof Goods And Services Sold | $1.8B |
Operating Income | $249M |
Selling General And Administrative | $476M |
Research And Development | $191M |
Operating Expenses | $771M |
Investment Income Net | - |
Net Interest Income | -$259M |
Interest Income | - |
Interest Expense | $259M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $236M |
Income Before Tax | -$55M |
Income Tax Expense | $19M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$74M |
Comprehensive Income Net Of Tax | - |
Ebit | $204M |
Ebitda | $440M |
Net Income | -$117M |
Field | Value (USD) |
---|---|
Total Assets | $3.5B |
Total Current Assets | $1.6B |
Cash And Cash Equivalents At Carrying Value | $111M |
Cash And Short Term Investments | $111M |
Inventory | $612M |
Current Net Receivables | $809M |
Total Non Current Assets | $1.9B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $732M |
Intangible Assets Excluding Goodwill | $732M |
Goodwill | $597M |
Investments | - |
Long Term Investments | - |
Short Term Investments | $1.9M |
Other Current Assets | $54M |
Other Non Current Assets | - |
Total Liabilities | $3.5B |
Total Current Liabilities | $1.1B |
Current Accounts Payable | $259M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $340M |
Total Non Current Liabilities | $2.4B |
Capital Lease Obligations | $107M |
Long Term Debt | $2.2B |
Current Long Term Debt | $324M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $2.6B |
Other Current Liabilities | $531M |
Other Non Current Liabilities | $94M |
Total Shareholder Equity | -$109M |
Treasury Stock | - |
Retained Earnings | -$607M |
Common Stock | $3.1M |
Common Stock Shares Outstanding | $309M |
Field | Value (USD) |
---|---|
Operating Cashflow | $295M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $236M |
Capital Expenditures | $52M |
Change In Receivables | - |
Change In Inventory | -$131M |
Profit Loss | - |
Cashflow From Investment | -$63M |
Cashflow From Financing | -$212M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$8M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$74M |
Field | Value (USD) |
---|---|
Gross Profit | $1B |
Total Revenue | $2.8B |
Cost Of Revenue | $1.8B |
Costof Goods And Services Sold | $1.8B |
Operating Income | $249M |
Selling General And Administrative | $476M |
Research And Development | $191M |
Operating Expenses | $771M |
Investment Income Net | - |
Net Interest Income | -$259M |
Interest Income | - |
Interest Expense | $259M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $236M |
Income Before Tax | -$55M |
Income Tax Expense | $19M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$74M |
Comprehensive Income Net Of Tax | - |
Ebit | $204M |
Ebitda | $440M |
Net Income | -$117M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Amneal Pharmaceuticals, Inc. (AMRX) is a leading developer and manufacturer of generic and specialty pharmaceuticals, with a broad portfolio that spans multiple dosage forms and therapeutic areas. Headquartered in Bridgewater, New Jersey, the company leverages its extensive expertise in drug development and manufacturing to provide high-quality, affordable medications to patients and healthcare providers. By focusing on innovation and operational excellence, Amneal is well-positioned to meet the evolving needs of the pharmaceutical market while driving sustainable growth and value for its stakeholders.